Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis

Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis

Purpose: This network meta-analysis was aimed to enhance the corresponding evidence with respect to the efficacy and safety of biologic treatments. Methods: PubMed and EMBASE database searches were conducted. Odds ratios were used to evaluate multi-aspect comparisons. SUCRA was used to analyze the r...

Full description

Bibliographic Details
Main Authors:	Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan
Format:	Article
Language:	English
Published:	Elsevier 2019-04-01
Series:	Journal of Pharmacological Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S1347861318302299

Similar Items

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
by: Klervi Golhen, et al.
Published: (2022-09-01)

Meta-analysis of the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis
by: Yanxia Cai, et al.
Published: (2025-01-01)

Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials
by: Cassyano Januário Correr, et al.
Published: (2013-01-01)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01)

Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis
by: Richard B. Warren, et al.
Published: (2024-11-01)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022-09-01)

Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
by: Bela J Shah, et al.
Published: (2020-01-01)

Efficacy and safety of secukinumab for moderate to severe plaque psoriasis in children: A report of 10 cases
by: FU Tao, et al.
Published: (2024-10-01)

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
by: Jing Yang, et al.
Published: (2020-01-01)

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
by: Jianfeng Zheng, et al.
Published: (2023-12-01)

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023-06-01)

Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice
by: Andrey L. Bakulev, et al.
Published: (2023-12-01)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
by: Ruggiero A, et al.
Published: (2023-11-01)

Moderate to severe psoriasis treatment challenges through the era of biological drugs
by: Júlia Vide, et al.
Published: (2017-10-01)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
by: Seung-Won Jung, et al.
Published: (2022-05-01)

Efficacy and Safety of Tripterygium wilfordii Hook F Versus Acitretin in Moderate to Severe Psoriasis Vulgaris: A Randomized Clinical Trial
by: Chao Wu, et al.
Published: (2015-01-01)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
by: Laura Salgado-Boquete, et al.
Published: (2021-06-01)

Ustekinumab for the treatment of moderate to severe psoriasis
by: E Gospodarevskaya, et al.
Published: (2009-10-01)

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
by: Jashin J. Wu, et al.
Published: (2023-12-01)

Centralised Biological Therapy Registry for Moderate to Severe Plaque Psoriasis – Overview and Methodology
by: Sutka R, et al.
Published: (2016-04-01)

Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023
by: Shan Huang, et al.
Published: (2024-08-01)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
by: Talamonti M, et al.
Published: (2023-04-01)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
by: Megna M, et al.
Published: (2022-07-01)

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis
by: Ya-Chu Tsai, et al.
Published: (2023-04-01)

Meta-analysis of efficacy and safety of adalimumab injection for arthropathic psoriasis
by: Nan LI, et al.
Published: (2019-02-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
by: Bruce W. Kirkham, et al.
Published: (2023-07-01)

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis
by: Andrew F. Alexis, et al.
Published: (2024-10-01)

Efficacy and safety of isotretinoin in comparison to methotrexate in the patients suffering from moderate-to-severe plaque psoriasis: A prospective cohort study
by: Suhrita Paul, et al.
Published: (2022-04-01)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-01-01)

Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis
by: Wenkai Zhang, et al.
Published: (2025-01-01)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
by: Ling Li, et al.
Published: (2023-05-01)

The thirteen problems /
by: Christie, Agatha, 1891-1976, author
Published: (2000)

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs
by: Leyla S. Namazova-Baranova, et al.
Published: (2021-11-01)

Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies
by: Edoardo Mortato, et al.
Published: (2023-06-01)

Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
by: Juncheng Wang, et al.
Published: (2023-06-01)

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study
by: Christopher Willy Schwarz, et al.
Published: (2021-10-01)

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
by: Richard B. Warren, et al.
Published: (2019-11-01)

The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn’s Disease: A Systematic Review
by: Ana Avedillo-Salas, et al.
Published: (2023-11-01)

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2024-12-01)